# OnCo record paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015" ;
  schema:name "KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma"@en ;
  schema:description "Head to head, the PD-1 antibody pembrolizumab held melanoma back longer, prolonged life and caused fewer severe side effects than ipilimumab, the CTLA-4 antibody that had been the first immunotherapy to extend survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1503093>, <https://clinicaltrials.gov/study/NCT01866319> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1503093> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Robert C, Schachter J, Long GV, et al." ;
  onco:related <https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/orr/> ;
  onco:trials <https://onco.cc/trials/keynote-006/> ;
  onco:people <https://onco.cc/people/caroline-robert/> .